Evidence map›Paper›PMID 35737182›Full record

ArticleIndian journal of pediatrics2023

Empirical Antitubercular Treatment for Lymphadenopathy: Are We Missing Lymphoma?

Amita Mahajan, Sameer Bakhshi, Manisha Singh, Rachna Seth, Nishant Verma, Sandeep Jain, Venkatraman Radhakrishnan, Piali Mandal, Ramandeep Singh Arora, Veronique Dinand and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The impact of tuberculosis misdiagnosis in Hodgkin lymphoma patients.The Indian journal of medical research · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Amita MahajanDepartment of Pediatric Oncology, Indraprastha Apollo Hospital, New Delhi, 110076, India. mahajanamita1@gmail.com.ORCID 0000-0002-7646-9468
Sameer BakhshiDepartment of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Manisha SinghDepartment of Medical and Pediatric Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
Rachna SethDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Nishant VermaDepartment of Pediatrics, King George's Medical University, Lucknow, Uttar Pradesh, India.
Sandeep JainDepartment of Pediatric Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India.
Venkatraman RadhakrishnanDepartment of Pediatric Oncology, Cancer Institute, Adyar, Chennai, Tamil Nadu, India.
Piali MandalDepartment of Pediatrics, Kalawati Saran Children's Hospital, New Delhi, India.
Ramandeep Singh AroraDepartment of Pediatric Oncology, Max Super Specialty Hospital, New Delhi, India.
Veronique DinandPalliative and Supportive Unit, BJ Wadia Hospital, Mumbai, Maharashtra, India.
Manas KalraDepartment of Pediatric Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Gauri KapoorDepartment of Pediatric Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India.
Mohammad SajidDepartment of Medical and Pediatric Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
Rakesh KumarDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Saumyaranjan MallickDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Ankit Taluja, Cankids Kidscan, New Delhi, India.
Jagdish ChandraDepartment of Pediatrics, Kalawati Saran Children's Hospital, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the proportion of patients who received empirical treatment with antitubercular therapy (ATT) prior to the diagnosis of Hodgkin lymphoma (HL) in the first multicentric, prospective study on HL from India, and to assess its impact on extent of disease at diagnosis and outcomes.

methodsChildren < 18 y with biopsy proven HL were enrolled in InPOG-HL-15-01. Along with other clinical and epidemiological data, history of prior treatment with ATT was documented. All patients received treatment as per a risk-stratified, response-adapted strategy.

resultsOut of 396, 115 (29%) children had received ATT prior to establishing a definitive diagnosis of HL. This cohort presented with advanced-stage disease (p = 0.001) and B symptoms (p = 0.001) in a higher proportion of cases. Consequently, those children were more likely to receive 6 rather than 4 cycles of chemotherapy (p = 0.001). They were more likely to have infradiaphragmatic involvement (p = 0.001). Overall survival and event-free survival were not different.

conclusionEmpirical treatment with ATT in children presenting with lymphadenopathy continues to be practiced widely in India. The delay in diagnosis may contribute to children presenting with advanced-stage disease warranting more intensive treatment for successful outcomes.

Indexed as

Hodgkin DiseaseLymphadenopathyAntineoplastic Combined Chemotherapy ProtocolsAntitubercular AgentsChildHumansProspective StudiesAntitubercular AgentsDelayed diagnosisHodgkin lymphomaTreatment burdenTuberculosis

Identifiers

PMID35737182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.